ArticleMolecular cancer research : MCR2014
MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival.
Article in Molecular cancer research : MCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Organ Donation for Research Biobanking Among Historically Marginalized Racial and Ethnic Groups: A Systematic Review.JAMA network open · 2025Pooled it
- A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers.Scientific reports · 2016Trial
- Characterization of anCancers · 2023Article
- A whole exome sequencing study to identify rare variants in multiplex families with alcohol use disorder.Frontiers in psychiatry · 2023Article
- Review
- The CRL4DTL E3 ligase induces degradation of the DNA replication initiation factor TICRR/TRESLIN specifically during S phase.Nucleic acids research · 2021Article
- The role of DDK and Treslin-MTBP in coordinating replication licensing and pre-initiation complex formation.Open biology · 2021Article
- Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer.International journal of molecular sciences · 2021Review
- MTBP promoted the proliferation, migration and invasion of colon cancer cells by activating the expression of ZEB2.Animal cells and systems · 2021Article
- MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting AgentsFrontiers in oncology · 2021Article
- Regulation of breast cancer metastasis signaling by miRNAs.Cancer metastasis reviews · 2020Review
- Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes.Scientific reports · 2020Article
- [MTBP regulates migration and invasion of prostate cancer cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019Article
- MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.Theranostics · 2019Article
- Article
- MTBP promotes migration and invasion by regulation of ZEB2-mediated epithelial-mesenchymal transition in lung cancer cells.OncoTargets and therapy · 2018Article
- Haploinsufficiency of the Myc regulator Mtbp extends survival and delays tumor development in aging mice.Aging · 2016Article
- microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.Oncotarget · 2016Article
- Leveraging big data to transform target selection and drug discovery.Clinical pharmacology and therapeutics · 2016Review
- Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis.Hepatoma research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledTriple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer commonly resistant to therapeutics that have been successful in increasing survival in patients with estrogen receptor-positive (ER(+)) and HER2(+) breast cancer. As such, identifying factors that contribute to poor patient outcomes and mediate the growth and survival of TNBC cells remain important areas of investigation. MTBP (MDM2-binding protein), a gene linked to cellular proliferation and a transcriptional target of the MYC oncogene, is overexpressed in human malignancies, yet its contribution to cancer remains unresolved. Evaluation of mRNA expression and copy number variation data from The Cancer Genome Atlas (TCGA) revealed that MTBP is commonly overexpressed in breast cancer and 19% show amplification of MTBP. Increased transcript or gene amplification of MTBP significantly correlated with reduced breast cancer patient survival. Further analysis revealed that while MTBP mRNA is overexpressed in both ER(+) and HER2(+) breast cancers, its expression is highest in TNBC. MTBP mRNA and protein levels were also significantly elevated in a panel of human TNBC cell lines. Knockdown of MTBP in TNBC cells induced apoptosis and significantly reduced TNBC cell growth and soft agar colony formation, which was rescued by expression of shRNA-resistant Mtbp. Notably, inducible knockdown of MTBP expression significantly impaired TNBC tumor growth, in vivo, including in established tumors. Thus, these data emphasize that MTBP is important for the growth and survival of TNBC and warrants further investigation as a potential novel therapeutic target. IMPLICATIONS: MTBP significantly contributes to breast cancer survival and is a potential novel therapeutic target in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.